54.32
Crispr Therapeutics Ag stock is traded at $54.32, with a volume of 1.72M.
It is up +2.84% in the last 24 hours and down -17.61% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$52.82
Open:
$52.81
24h Volume:
1.72M
Relative Volume:
0.54
Market Cap:
$4.94B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-19.40
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-9.06%
1M Performance:
-17.61%
6M Performance:
+13.38%
1Y Performance:
+14.36%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CRSP
Crispr Therapeutics Ag
|
54.32 | 5.24B | 170.10M | -239.59M | -191.20M | -2.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
Feb-03-25 | Initiated | H.C. Wainwright | Buy |
Aug-06-24 | Reiterated | Needham | Buy |
Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
Jun-28-24 | Resumed | Guggenheim | Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-27-23 | Initiated | Mizuho | Buy |
Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
May-30-23 | Initiated | William Blair | Outperform |
Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Mar-17-23 | Initiated | Bryan Garnier | Buy |
Mar-07-23 | Initiated | Robert W. Baird | Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Underweight |
Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
Dec-10-20 | Reiterated | Needham | Buy |
Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-05-20 | Initiated | BofA Securities | Buy |
Jul-28-20 | Reiterated | Needham | Buy |
Jul-14-20 | Initiated | SunTrust | Buy |
Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
Mar-05-20 | Initiated | Stifel | Hold |
Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-01-19 | Initiated | Jefferies | Buy |
Jul-26-19 | Initiated | Canaccord Genuity | Buy |
Jun-10-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-14-19 | Initiated | William Blair | Mkt Perform |
Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
Watch for Trend Continuation in CRISPR Therapeutics AG Next WeekJuly 2025 Rallies & Free AI Powered Buy and Sell Recommendations - thegnnews.com
Vestmark Advisory Solutions Inc. Sells 18,728 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Bernstein Remains a Hold on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Fox Run Management L.L.C. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance
EverSource Wealth Advisors LLC Purchases 84,708 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR-based therapies signal a new direction in tackling infectious diseases - Clinical Trials Arena
CRISPR Therapeutics AG Shows Support at Fibonacci Level2025 Key Highlights & Expert-Curated Trade Recommendations - sundaytimes.kr
Virtu Financial LLC Purchases New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns - Yahoo Finance
Benjamin Edwards Inc. Purchases 5,853 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Pattern Scan Adds CRISPR Therapeutics AG to WatchlistPrice Action & Weekly Breakout Stock Alerts - kangso.co.kr
Crispr Therapeutics AG: Stock Surge Amid Clinical Advances - TipRanks
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure? - Yahoo Finance
Crispr Therapeutics shares rise 1.48% premarket after ReproCELL Incorporated receives ¥5.3 million in funding. - AInvest
Equities Analysts Offer Predictions for CRSP Q4 Earnings - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha
Blair William & Co. IL Cuts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics Bets Big On Gene-Editing Breakthroughs - Finimize
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Cetera Investment Advisers - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - MSN
Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Chardan Capital Has Strong Estimate for CRSP FY2026 Earnings - MarketBeat
Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Research Analysts Issue Forecasts for CRSP FY2025 Earnings - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - AOL.com
Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Q3 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - MarketBeat
Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crispr Therapeutics Ag Stock (CRSP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):